Implementation of Hepatic Artery Infusion Pump Therapy: Real‐World Single‐Center Experience
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.27859 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Robert Connor Chick und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Liver Neoplasms, Hepatic Artery, Colorectal Neoplasms, Infusions, Intra-Arterial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Objectives Hepatic artery infusion pump (HAIP) therapy is an available option at highly specialized centers to treat unresectable liver tumors (e.g., colorectal liver metastases [CRLM]). This study describes the safety and outcomes of HAIP program implementation at an academic‐based cancer center.
Methods
Patients who underwent HAIP placement (2021–2023) were included. Categorical and continuous variables were compared using Chi‐square and Kruska–Wallis tests, respectively. Survival and variables associated with survival were calculated using the Kaplan–Meier method and Cox proportional hazards model, respectively.
Results
Of the 26 HAIP procedures for unresectable CRLM, four were done as adjuvant therapy. Median duration of HAIP therapy was 9.2 months and four patients subsequently underwent hepatectomy. Complication rate was 37.5%, with biliary complication rate of 23.1%. Median overall survival (OS) from date of diagnosis was 55.2 months. Concurrent primary tumor resection was associated with inferior OS ( p = 0.030). Multivariable regression did not identify independent predictors of OS. Progression‐free survival from time of HAIP placement was 7.8 months.
Conclusions
HAIP placement was technically successful in most patients with an acceptable complication rate. Survival outcomes were comparable with those described in the literature for HAIP therapy in combination with systemic therapy. The significant difference in outcomes for those with concurrent colectomy warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Surgical Oncology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA.
- Department of Surgery, University of Virginia, Charlottesville, Virgina, USA.
- College of Medicine, The Ohio State University, Columbus, Ohio, USA.
- Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Department of Surgery, Division of Surgical Oncology, University of Illinois Chicago, Chicago, Illinois, USA.
- Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Robert Connor Chick
Zitieren
APA
Connor Chick, R., Ruff, S. M., Monasterio, J., Neilson, T., Tsai, S., Ejaz, A., Tsung, A., & Kim, A. C. (2025). Implementation of Hepatic Artery Infusion Pump Therapy: Real‐World Single‐Center Experience. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27859
Vancouver
Connor Chick R, Ruff SM, Monasterio J, Neilson T, Tsai S, Ejaz A, et al. Implementation of Hepatic Artery Infusion Pump Therapy: Real‐World Single‐Center Experience. Journal of Surgical Oncology. 2025. doi:10.1002/jso.27859
BibTeX
@article{ConnorChick2025,
author = {Connor Chick, Robert and Ruff, Samantha M and Monasterio, Julia and Neilson, Taylor and Tsai, Susan and Ejaz, Aslam and Tsung, Allan and Kim, Alex C},
title = {Implementation of Hepatic Artery Infusion Pump Therapy: Real‐World Single‐Center Experience},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.27859}
}
EUVIMED